Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
about
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
description
clinical trial
@en
klinisch onderzoek
@nl
name
Study of Radium-223 Dichloride ...... itive Metastatic Breast Cancer
@en
type
label
Study of Radium-223 Dichloride ...... itive Metastatic Breast Cancer
@en
prefLabel
Study of Radium-223 Dichloride ...... itive Metastatic Breast Cancer
@en
P17
P131
P1476
A Phase II Randomized, Double- ...... l Treatment Background Therapy
@en
P17
P3098
NCT02258464
P580
2015-03-02T00:00:00Z
P582
2019-06-19T00:00:00Z